Larimar Therapeutics, Inc.
LRMR
$4.36
$0.092.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.19% | 7.27% | 4.22% | 8.86% | 11.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.91% | 63.68% | 89.79% | 89.50% | 64.86% |
| Operating Income | -64.91% | -63.68% | -89.79% | -89.50% | -64.86% |
| Income Before Tax | -72.98% | -74.32% | -105.54% | -103.79% | -71.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.98% | -74.32% | -105.54% | -103.79% | -71.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.98% | -74.32% | -105.54% | -103.79% | -71.05% |
| EBIT | -64.91% | -63.68% | -89.79% | -89.50% | -64.86% |
| EBITDA | -65.13% | -63.88% | -90.07% | -89.87% | -65.18% |
| EPS Basic | -27.14% | -39.46% | -69.03% | -67.41% | -40.03% |
| Normalized Basic EPS | -27.15% | -39.47% | -69.03% | -67.39% | -40.02% |
| EPS Diluted | -27.14% | -39.46% | -69.03% | -67.41% | -40.03% |
| Normalized Diluted EPS | -27.15% | -39.47% | -69.03% | -67.39% | -40.02% |
| Average Basic Shares Outstanding | 40.12% | 24.44% | 18.99% | 20.02% | 24.59% |
| Average Diluted Shares Outstanding | 40.12% | 24.44% | 18.99% | 20.02% | 24.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |